Compares two diabetes drug combinations in adults newly diagnosed with type 2 diabetes
Compares sitagliptin and linagliptin, each with metformin and empagliflozin, in type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes
Key facts
- Where
- Karachi, PakistanSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 55 years old?
Source: NCT07452913, who can take part
Where in Pakistan
- National Medical Center KarachiKarachi, PakistanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bahria University
- Trial code
- NCT07452913
- Record updated
- 5 March 2026
- Original description
This clinical trial aims to evaluate and compare the comparative efficacy and safety of Metformin-Empagliflozin-Sitagliptin vs. Metformin-Empagliflozin-Linagliptin in newly diagnosed Type 2 Diabetes Mellitus patients.Read full original descriptionShow less
Comparative Efficacy and Safety of Metformin-Empagliflozin-Sitagliptin vs. Metformin-Empagliflozin-Linagliptin as Initial Triple Therapy in Type 2 Diabetes Mellitus
This clinical trial aims to evaluate and compare the comparative efficacy and safety of Metformin-Empagliflozin-Sitagliptin vs. Metformin-Empagliflozin-Linagliptin in newly diagnosed Type 2 Diabetes Mellitus patients.
The study will involve 110 participants, aged 30-55, enrolled at the National Medical Centre, Karachi, Pakistan. The study involves two groups, subjects will receive the following treatments: Group A will receive Tab Metformin 1000mg + Tab Empagliflozin 12.5mg (FDC) + Tab Sitagliptin 50mg, whereas Group B will receive Tab Metformin 1000mg + Tab Empagliflozin 12.5mg + Tab Linagliptin 2.5mg (FDC) per orally, once daily, for 90 days. Safety and efficacy will be assessed through anthropometric measurements and lab investigations at baseline, 6 weeks, and 12 weeks, with weekly monitoring of blood sugar levels. The total duration of the study will be 6 months, with a 3-month individual treatment period.
Inclusion: Males and Females; Age 30-55 years; HbA1c = ≥ 8.5 <10 mmol/mol (ADA. 2025); BMI >18.5- <29.9 (WHO Asian Criteria); Treatment naïve patients; With / without dyslipidemia.
Exclusion: Systemic diseases such as: hypertension, thyroid, liver, renal diseases etc; Known allergy or intolerance to Metformin, Empagliflozin, Sitagliptin or Linagliptin; HbA1c >10 mmol/mol; BMI > 30 kg/m²; Pregnancy or lactation.